Epigenetic repression of the dopamine receptor D4 in pediatric tumors of the central nervous system

Journal of Neuro-Oncology

Volumn 116, Issue 2, 2014, Pages 237-249

  Unland, Rebekka ^a   Kerl, Kornelius ^a   Schlosser, Sabrina ^a   Farwick, Nicole ^a   Plagemann, Tanja ^a   Lechtape, Birigit ^a   Clifford, Steven C ^b   Kreth, Jonas H ^c   Gerss, Joachim ^d   Mühlisch, Jörg ^a   Richter, Günther H S ^e   Hasselblatt, Martin ^a   Frühwald, Michael C ^a,f  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^f Children's Hospital Augsburg   (Germany)

Author keywords

CNS tumors of children; Dopamine receptor D4 (DRD4); Epigenetic silencing; ERK1 2 signaling; EZH2

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DOPAMINE 4 RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TRANSCRIPTION FACTOR EZH2;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CENTRAL NERVOUS SYSTEM TUMOR; CHILDHOOD CANCER; CONTROLLED STUDY; DNA METHYLATION; DRD4 GENE; EMBRYO; ENZYME ACTIVATION; EPENDYMOMA; EPIGENETIC REPRESSION; GENE EXPRESSION; GLIOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MEDULLOBLASTOMA; NEUROENDOCRINE TUMOR; PROMOTER REGION;

APOPTOSIS; AZACITIDINE; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHROMATIN ASSEMBLY AND DISASSEMBLY; DOSE-RESPONSE RELATIONSHIP, DRUG; EPIGENESIS, GENETIC; FEMALE; HUMANS; HYDROXAMIC ACIDS; MALE; MEDULLOBLASTOMA; NEUROECTODERMAL TUMORS, PRIMITIVE; RECEPTORS, DOPAMINE D4; SULFITES; TUMOR CELLS, CULTURED;

EID: 84893118647     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-013-1313-1     Document Type: Article

References (48)

1. Frühwald MC, Rutkowski S (2011) Tumors of the central nervous system in children and adolescents. Dtsch Arztebl Int 108:390-397. doi: 10.3238/arztebl.2011.0390
2. Schlosser S, Wagner S, Muhlisch J, Hasselblatt M, Gerss J, Wolff JE, Frühwald MC (2010) MGMT as a potential stratification marker in relapsed high-grade glioma of children: the HIT-GBM experience. Pediatr Blood Cancer 54:228-237. doi: 10.1002/pbc.22323
3. Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomaki P, Lang JC et al (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132-138. doi: 10.1038/72785
4. Frühwald MC, O'Dorisio MS, Dai Z, Tanner SM, Balster DA, Gao X, Wright FA, Plass C (2001) Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas - implications for tumor biology and potential clinical utility. Oncogene 20:5033-5042. doi: 10.1038/sj.onc.1204613
5. Lindsey JC, Lusher ME, Anderton JA, Bailey S, Gilbertson RJ, Pearson AD, Ellison DW, Clifford SC (2004) Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling. Carcinogenesis 25:661-668. doi: 10.1093/carcin/bgh055
6. Muhlisch J, Schwering A, Grotzer M, Vince GH, Roggendorf W, Hagemann C, Sorensen N, Rickert CH, Osada N, Jurgens H et al (2006) Epigenetic repression of RASSF1A but not CASP8 in supratentorial PNET (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of childhood. Oncogene 25:1111-1117. doi: 10.1038/sj.onc.1209137
7. Muhlisch J, Bajanowski T, Rickert CH, Roggendorf W, Wurthwein G, Jurgens H, Frühwald MC (2007) Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. J Neurooncol 83:17-29. doi: 10.1007/s11060-006-9309-8
8. McCabe MT, Brandes JC, Vertino PM (2009) Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res 15:3927-3937. doi: 10.1158/1078-0432.CCR-08-2784
9. Kouzarides T (2007) Chromatin modifications and their function. Cell 128:693-705. doi: 10.1016/j.cell.2007.02.005
10. Simon JA, Lange CA (2008) Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res 647:21-29. doi: 10.1016/j.mrfmmm.2008.07.010
11. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189-225
12. Oak JN, Oldenhof J, Van Tol HH (2000) The dopamine D(4) receptor: one decade of research. Eur J Pharmacol 405:303-327
13. Dai Z, Weichenhan D, Wu YZ, Hall JL, Rush LJ, Smith LT, Raval A, Yu L, Kroll D, Mühlisch J et al (2002) An AscI boundary library for the studies of genetic and epigenetic alterations in CpG islands. Genome Res 12:1591-1598. doi: 10.1101/gr.197402
14. Hasselblatt M, Muhlisch J, Wrede B, Kallinger B, Jeibmann A, Peters O, Kutluk T, Wolff JE, Paulus W, Frühwald MC (2009) Aberrant MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation in choroid plexus tumors. J Neurooncol 91:151-155. doi: 10.1007/s11060-008-9694-2
15. Richter GH, Plehm S, Fasan A, Rossler S, Unland R, Bennani-Baiti IM, Hotfilder M, Lowel D, von Luettichau I, Mossbrugger I et al (2009) EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci USA 106:5324-5329. doi: 10.1073/pnas.0810759106
16. Oak JN, Lavine N, Van Tol HH (2001) Dopamine D(4) and D(2L) receptor stimulation of the mitogen-activated protein kinase pathway is dependent on trans-activation of the platelet-derived growth factor receptor. Mol Pharmacol 60:92-103
17. Gill RS, Hsiung MS, Sum CS, Lavine N, Clark SD, Van Tol HH (2010) The dopamine D4 receptor activates intracellular platelet-derived growth factor receptor beta to stimulate ERK1/2. Cell Signal 22:285-290. doi: 10.1016/j.cellsig.2009.09.031
18. Pfister S, Schlaeger C, Mendrzyk F, Wittmann A, Benner A, Kulozik A, Scheurlen W, Radlwimmer B, Lichter P (2007) Array-based profiling of reference-independent methylation status (aPRIMES) identifies frequent promoter methylation and consecutive downregulation of ZIC2 in pediatric medulloblastoma. Nucleic Acids Res 35:e51. doi: 10.1093/nar/gkm094
19. Hamilton DW, Lusher ME, Lindsey JC, Ellison DW, Clifford SC (2005) Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. Cancer Lett 227:75-81. doi: 10.1016/j.canlet.2004.11.044
20. Rush LJ, Dai Z, Smiraglia DJ, Gao X, Wright FA, Frühwald M, Costello JF, Held WA, Yu L, Krahe R et al (2001) Novel methylation targets in de novo acute myeloid leukemia with prevalence of chromosome 11 loci. Blood 97:3226-3233
21. Freed WJ, Chen J, Backman CM, Schwartz CM, Vazin T, Cai J, Spivak CE, Lupica CR, Rao MS, Zeng X (2008) Gene expression profile of neuronal progenitor cells derived from hESCs: activation of chromosome 11p15.5 and comparison to human dopaminergic neurons. PLoS One 3:e1422. doi: 10.1371/journal.pone.0001422
22. Pai S, Verrier F, Sun H, Hu H, Ferrie AM, Eshraghi A, Fang Y (2012) Dynamic mass redistribution assay decodes differentiation of a neural progenitor stem cell. J Biomol Screen 17:1180-1191. doi: 10.1177/1087057112455059
23. de Bustros A, Nelkin BD, Silverman A, Ehrlich G, Poiesz B, Baylin SB (1988) The short arm of chromosome 11 is a "hot spot" for hypermethylation in human neoplasia. Proc Natl Acad Sci USA 85:5693-5697
24. Cichon S, Nothen MM, Wolf HK, Propping P (1996) Lack of imprinting of the human dopamine D4 receptor (DRD4) gene. Am J Med Genet 67:229-231
25. Teunis MA, Kavelaars A, Voest E, Bakker JM, Ellenbroek BA, Cools AR, Heijnen CJ (2002) Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J 16:1465-1467. doi: 10.1096/fj.02-0145fje
26. Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S (2004) Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 10:4349-4356. doi: 10.1158/1078-0432.CCR-04-0059
27. Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, Basu S (2004) Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am J Physiol Heart Circ Physiol 287:H1554-H1560. doi: 10.1152/ajpheart.00272.2004
28. Basu S, Dasgupta PS (1997) Alteration of dopamine D2 receptors in human malignant stomach tissue. Dig Dis Sci 42:1260-1264
29. Basu S, Dasgupta PS (1999) Decreased dopamine receptor expression and its second-messenger cAMP in malignant human colon tissue. Dig Dis Sci 44:916-921
30. Barili P, Bronzetti E, Felici L, Ferrante F, Ricci A, Zaccheo D, Amenta F (1996) Age-dependent changes in the expression of dopamine receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 71:45-50
31. Noain D, Avale ME, Wedemeyer C, Calvo D, Peper M, Rubinstein M (2006) Identification of brain neurons expressing the dopamine D4 receptor gene using BAC transgenic mice. Eur J Neurosci 24:2429-2438. doi: 10.1111/j.1460-9568.2006. 05148.x
32. Nguyen CT, Weisenberger DJ, Velicescu M, Gonzales FA, Lin JC, Liang G, Jones PA (2002) Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2′- deoxycytidine. Cancer Res 62:6456-6461
33. Rada-Iglesias A, Enroth S, Andersson R, Wanders A, Pahlman L, Komorowski J, Wadelius C (2009) Histone H3 lysine 27 trimethylation in adult differentiated colon associated to cancer DNA hypermethylation. Epigenetics 4:107-113
34. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K (2003) EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323-5335. doi: 10.1093/emboj/cdg542
35. Chang CJ, Hung MC (2012) The role of EZH2 in tumour progression. Br J Cancer 106:243-247. doi: 10.1038/bjc.2011.551
36. Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L, Mohammad HP, Chen W, Daniel VC, Yu W et al (2007) A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39:237-242. doi: 10.1038/ng1972
37. McGarvey KM, Van Neste L, Cope L, Ohm JE, Herman JG, Van Criekinge W, Schuebel KE, Baylin SB (2008) Defining a chromatin pattern that characterizes DNA-hypermethylated genes in colon cancer cells. Cancer Res 68:5753-5759. doi: 10.1158/0008-5472.CAN-08-0700
38. Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, Weinberg RA (2008) An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40:499-507. doi: 10.1038/ng.127
39. Fujii S, Ito K, Ito Y, Ochiai A (2008) Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem 283:17324-17332. doi: 10.1074/jbc.M800224200
40. Takebayashi S, Nakao M, Fujita N, Sado T, Tanaka M, Taguchi H, Okumura K (2001) 5-Aza-2′-deoxycytidine induces histone hyperacetylation of mouse centromeric heterochromatin by a mechanism independent of DNA demethylation. Biochem Biophys Res Commun 288:921-926. doi: 10.1006/bbrc.2001.5863
41. Dhillon AS, Hagan S, Rath O, Kolch W (2007) MAP kinase signalling pathways in cancer. Oncogene 26:3279-3290. doi: 10.1038/sj.onc.1210421
42. Kim EK, Choi EJ (2010) Pathological roles of MAPK signaling pathways in human diseases. Biochim Biophys Acta 1802:396-405. doi: 10.1016/j.bbadis.2009. 12.009
43. Hynes NE, MacDonald G (2009) ErbB receptors and signaling pathways in cancer. Curr Opin Cell Biol 21:177-184. doi: 10.1016/j.ceb.2008.12.010
44. Jones DT, Gronych J, Lichter P, Witt O, Pfister SM (2012) MAPK pathway activation in pilocytic astrocytoma. Cell Mol Life Sci 69:1799-1811. doi: 10.1007/s00018-011-0898-9
45. Menard C, Hein P, Paquin A, Savelson A, Yang XM, Lederfein D, Barnabe-Heider F, Mir AA, Sterneck E, Peterson AC et al (2002) An essential role for a MEK-C/EBP pathway during growth factor-regulated cortical neurogenesis. Neuron 36:597-610
46. Hadari YR, Kouhara H, Lax I, Schlessinger J (1998) Binding of Shp2 tyrosine phosphatase to FRS2 is essential for fibroblast growth factor-induced PC12 cell differentiation. Mol Cell Biol 18:3966-3973
47. Samuels IS, Karlo JC, Faruzzi AN, Pickering K, Herrup K, Sweatt JD, Saitta SC, Landreth GE (2008) Deletion of ERK2 mitogen-activated protein kinase identifies its key roles in cortical neurogenesis and cognitive function. J Neurosci 28:6983-6995. doi: 10.1523/JNEUROSCI.0679-08.2008
48. Sato T, Joyner AL, Nakamura H (2004) How does Fgf signaling from the isthmic organizer induce midbrain and cerebellum development? Dev Growth Differ 46:487-494. doi: 10.1111/j.1440-169x.2004.00769.x